Patterns of phosphoantigen stimulation of human Vgamma9/Vdelta2 T cell clones include Th0 cytokines.
This paper examines functional properties of human Vgamma9/Vdelta2 T cell lines and clones generated by in vitro culture with synthetic and natural (mycobacterial) phosphoantigenic molecules. It confirms the broad reactivity of Vgamma9/Vdelta2 T cell lines and clones toward phosphoantigens. Optimal recognition of phosphoantigens by Vgamma9/Vdelta2 T cells required accessory cells to occur, but did not require specialized antigen presenting cells. However, species origin of the APC was irrelevant as proliferation of Vgamma9/Vdelta2 T cells occurred in the presence of syngeneic, allogeneic or xenogeneic APC and was not restricted to APC of particular tissue origin. Moreover antigen uptake and processing was not required for recognition by Vgamma9/ Vdelta2 cells, as evidenced by the ability of fixed APCs to present phosphoantigens. Similarly, the expression of classical MHC class I and class II molecules was not required for phosphoantigen recognition by gammadelta T cells. However, gammadelta T cell clones responded to stimulation by several cytokines including IL-12, IFNgamma and TNFalpha. Finally, Vgamma9/Vdelta2 T cell clones preferentially produced both IFN-gamma and IL-4 in response to PHA or TUBAg stimulation, revealing that a Th0 pattern of cytokine production is frequent among these cells.
Sireci
G
G
Institute of General Pathology, University of Palermo, Italy.
Champagne
E
E
Fourniè
J J
JJ
Dieli
F
F
Salerno
A
A
D000907:Antibodies, Bacterial / Q000494:pharmacology; D000911:Antibodies, Monoclonal / Q000276:immunology; D000938:Antigen-Presenting Cells / Q000737:chemistry / Q000276:immunology; D000942:Antigens, Bacterial / Q000737:chemistry / Q000276:immunology*; D002999:Clone Cells; D016207:Cytokines / Q000096:biosynthesis*; D004306:Dose-Response Relationship, Immunologic; D004797:Enzyme-Linked Immunosorbent Assay; D045782:Hemiterpenes; D006600:Hexosephosphates / Q000494:pharmacology; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis / Q000494:pharmacology; D018664:Interleukin-12 / Q000494:pharmacology; D007376:Interleukin-2 / Q000096:biosynthesis; D015847:Interleukin-4 / Q000096:biosynthesis; D008213:Lymphocyte Activation; D019907:Mycobacterium fortuitum / Q000276:immunology*; D009943:Organophosphorus Compounds / Q000494:pharmacology; D010428:Pentosephosphates; D010766:Phosphorylation; D016133:Polymerase Chain Reaction; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000276:immunology*; D012267:Ribosemonophosphates / Q000494:pharmacology; D013601:T-Lymphocytes / Q000276:immunology*; D014158:Transcription, Genetic; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D000942:Antigens, Bacterial; D016207:Cytokines; D045782:Hemiterpenes; D006600:Hexosephosphates; D007376:Interleukin-2; D009943:Organophosphorus Compounds; D010428:Pentosephosphates; D016692:Receptors, Antigen, T-Cell, gamma-delta; D012267:Ribosemonophosphates; D014409:Tumor Necrosis Factor-alpha; C031154:ribose 1-phosphate; C054739:xylose 1-phosphate; D018664:Interleukin-12; D015847:Interleukin-4; C004809:isopentenyl pyrophosphate; C043060:3,3-dimethylallyl pyrophosphate; D007371:Interferon-gamma